No Data
No Data
Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix
INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALSThe study investigated 123 metastatic ovarian cancer
ANGLE Inks Supplier Agreement With AstraZeneca To Develop A Parsortix-Based Androgen Receptor Detection Assay For Use In Prostate Cancer Studies
Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion exp
Liquid Biopsy Firm Angle Signs New Commercial Agreement With AstraZeneca
ANGLE Achieves Breakthrough With EU Patent for CellKeep Technology, With the US to Follow
Angle PLC Announces Parsortix HER2 Assay Showcased at AACR 2024
PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCECTC HER2 assay being developed for HER2 targeted drugs and antibody drug conjugates presented at internationally renowned A
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
No Data